Epsilogen
Founded 2016 · 33 employees on LinkedIn · 8 known investors
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is in clinical development for ovarian cancer.
Founders & leadership
Investors · 8
Competitors · 2
by search overlap
Biogen Idec8 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Epsilogen for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Epsilogen do?
- Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is in clinical development for ovarian cancer.
- Who are Epsilogen's investors?
- Epsilogen's investors include 3B Future Health Fund, AlbionVC, ALSA Ventures, Epidarex Capital, Global BioAccess Fund, Novartis Venture Fund, UCL Technology Fund, BioGeneration Ventures.